The philosophy of cancer treatment always has “pain, without gain” of the leg, and the closure of the directed path and the “tolerated maximum dose”, explained Ben Zestkind, co -founder, president and CEO of immuneration. Now Zijnkind and his clinical stage biotechnology company are trying to try something new in the field of pancreas cancer.
Instead of closing a road throughout the day and then dosing a patient at the maximum dose that can be tolerated, the company is developing a new approach where this path periodically closes and then “hits the disease very strong for a very difficult certainty.” The first clinical results of this approach aimed at the Mitogen Activated Mitogen Puttlement (MAP) protein pathway are promising.
In our season 2 of the pivot podcast – April – June, we focus on innovations in oncology, beginning with the high objective of immuneing to make cancer seclala as a chronic disease.
You can see the whole video here:
